News

H2020-EIC-SMEInst-2018-2020 – Update Brexit

Published on
| 6 years ago
Programmes
  • SME Instrument
  • EIC Pilot

As of 1 February 2020, the United Kingdom formally leaves the European Union. In accordance with the Withdrawal Agreement, applicants located in the UK are:

a. Eligible for grants (including the EIC Accelerator) until the end of the transition period on 31 December 2020. They are entitled to receive EU grant funding to carry out their projects until the projects’ lifetime is completed, including projects finishing after the end of the transition period.

b. Not eligible for EIC Accelerator Pilot equity support as of 1 February 2020.

The section on eligible countries under the heading Topic conditions and documents has also been updated accordingly.

Source: Funding and Tender Portal

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2049 articles available Browse all news
  • EIC

EIC Work Programme 2027 adopted

The 2027 work programme opens funding opportunities worth over €1.8 billion for strategic technologies and scaling up companies. The EIC work programme 2027 details the funding in six main schemes: EIC Pathfinder EIC Transition Advanced Innovation Challenges EIC Accelerator The EIC Strategic Technologies for Europe Platform (STEP) Scale Up EIC...

Read more
  • Defence
  • DIRS

Start2Def 2026 call open

The Start2Def 2026 selection process opened on 4 November 2026. Belgian startups and small SMEs can submit proof-of-concept ideas for one of two defence-related challenges.

Read more

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.